Savar

Overview

Savar is a Chilean biotechnology company based in Santiago, Chile, focused on developing biological therapies for neurodegenerative diseases. The company specializes in recombinant protein therapeutics targeting neuroprotection, with programs in Alzheimer's disease, Parkinson's disease, and other neurological conditions[@savar2024].

Founded in 2018, Savar has built a protein engineering and manufacturing platform focused on developing neuroprotective proteins. The company's approach involves engineering naturally-occurring neuroprotective proteins to enhance their therapeutic potential and develop them as biopharmaceuticals.

Company Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | Santiago, Chile |
| Founded | 2018 |
| Focus Areas | Recombinant proteins, Neuroprotection, Biologics |
| Employees | ~35 |
| Stage | Preclinical to clinical |

History and Development

Founding

Savar was founded by a team of Chilean scientists with expertise in protein engineering and neuroscience:

• Dr. Oscar Aravena (CEO): Protein engineering background, previous positions at leading biotech companies
• Dr. Monica Valenzuela: Neuroscience research background, focus on neuroprotection mechanisms
• Dr. Roberto Fernandez: Business leadership, previous entrepreneurial experience

Technology Platform Development

The company has developed core capabilities in:

...

Overview

Savar is a Chilean biotechnology company based in Santiago, Chile, focused on developing biological therapies for neurodegenerative diseases. The company specializes in recombinant protein therapeutics targeting neuroprotection, with programs in Alzheimer's disease, Parkinson's disease, and other neurological conditions[@savar2024].

Founded in 2018, Savar has built a protein engineering and manufacturing platform focused on developing neuroprotective proteins. The company's approach involves engineering naturally-occurring neuroprotective proteins to enhance their therapeutic potential and develop them as biopharmaceuticals.

Company Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | Santiago, Chile |
| Founded | 2018 |
| Focus Areas | Recombinant proteins, Neuroprotection, Biologics |
| Employees | ~35 |
| Stage | Preclinical to clinical |

History and Development

Founding

Savar was founded by a team of Chilean scientists with expertise in protein engineering and neuroscience:

• Dr. Oscar Aravena (CEO): Protein engineering background, previous positions at leading biotech companies
• Dr. Monica Valenzuela: Neuroscience research background, focus on neuroprotection mechanisms
• Dr. Roberto Fernandez: Business leadership, previous entrepreneurial experience

Technology Platform Development

The company has developed core capabilities in:

Protein Engineering:

• Recombinant protein expression and purification
• Protein optimization for enhanced activity
• Fc fusion technology for extended half-life

Manufacturing:

• Mammalian cell expression systems
• GMP-compliant production processes
• Scale-up capabilities

Recent Progress

Savar has advanced its programs:

• 2019: First lead protein candidate nominated
• 2021: Completed preclinical studies for SAV-001
• 2023: Entered regulatory submission process
• 2024: Received approval for first clinical trial application

Technology Platform

Recombinant Neuroprotective Proteins

Savar's核心技术 involves engineering naturally-occurring neuroprotective proteins:

Approach:

• Identify endogenous neuroprotective proteins
• Engineer for enhanced potency and pharmacokinetics
• Develop as recombinant biopharmaceuticals

Advantages:

• Well-characterized mechanisms of action
• Human proteins with favorable safety profiles
• Potential for disease modification

Protein Engineering Capabilities

Expression Systems:

• CHO (Chinese Hamster Ovary) cells for complex proteins
• Bacterial systems for simpler proteins
• Yeast for rapid prototyping

Engineering Strategies:

• Affinity maturation for enhanced binding
• Fc fusion for half-life extension
• Point mutations for improved activity

Formulation:

• Liquid formulation development
• Lyophilized formulations for stability
• Device development for delivery

Pipeline Overview

| Program | Target | Stage | Indication |
|---------|--------|-------|------------|
| SAV-001 | Neuronal survival | Phase 1准备 | Alzheimer's disease |
| SAV-002 | Synaptic protection | Preclinical | Alzheimer's disease |
| SAV-003 | Dopaminergic neuroprotection | Discovery | Parkinson's disease |
| SAV-004 | Myelin protection | Discovery | Multiple sclerosis |

SAV-001 (Lead Program)

SAV-001 is a recombinant neuroprotective protein being developed for Alzheimer's disease:

Mechanism:

• Promotes neuronal survival through multiple pathways
• Reduces apoptotic cell death
• Supports synaptic function

Preclinical Results:

• Demonstrated neuroprotection in cellular models
• Improved cognitive performance in transgenic mouse models
• Favorable safety and tolerability in toxicology studies

Clinical Status:

• Received regulatory approval for Phase 1 study
• Study initiation planned for 2024

Research Partnerships

Academic Collaborations

University of Chile:

• Joint research on protein mechanisms
• Graduate student training
• Access to research facilities

Pontifical Catholic University of Chile:

• Clinical research capabilities
• Patient sample access
• Biomarker development collaboration

International Collaborations

Pharmaceutical Partnerships:

• Research collaboration with global pharma for SAV-002
• Manufacturing partnership for clinical supply
• Commercialization discussions for Latin American markets

Consortium Membership:

• Latin American Biopharmaceutical Network
• International Neurodegeneration Research Consortium

Manufacturing Capabilities

Production Facilities

Savar operates manufacturing capabilities in Santiago:

• Research laboratory: Protein discovery and development
• Pilot plant: Scale-up production for preclinical studies
• Quality control: Analytical testing facilities

GMP Manufacturing

The company has established:

• Cell banking: Master cell bank and working cell bank
• Upstream production: Bioreactor-based protein production
• Downstream purification: Protein purification and characterization
• Quality systems: GMP-compliant quality management

Regulatory Status

Chilean Regulatory

Savar operates under oversight from:

• ISP: Regulatory authority for biological products
• ANID: Science and technology funding
• CORFO: Economic development support

International Strategy

The company is pursuing global development:

• FDA: Pre-IND meeting completed
• EMA: Scientific advice received
• Regional: Latin American regulatory harmonization

Financial Status

Funding History

Savar has raised funding through:

• Founders: Initial founder investment
• Seed round: Funding from Chilean angel investors
• Series A: Primary development funding
• Grants: Non-dilutive funding from government sources

Investment Needs

The company is seeking additional funding to:

• Complete Phase 1 clinical trials
• Advance pipeline programs
• Build commercial capabilities

Strategic Focus

Near-term Priorities

Initiate Phase 1 trial: Begin clinical development of SAV-001

Advance SAV-002: Progress toward IND submission

Expand partnerships: Establish additional pharmaceutical collaborations

Long-term Vision

Savar aims to become a leading biopharmaceutical company in Latin America:

• Regional presence: First Chilean company with neurodegenerative biologics in clinic
• Pipeline expansion: Multiple programs across neurological conditions
• Global reach: International market access through partnerships

Challenges

Technical

• Manufacturing scale: Scaling production for clinical trials
• Clinical translation: Demonstrating efficacy in humans
• Biomarkers: Developing patient selection biomarkers

Commercial

• Competition: Competing with well-resourced global companies
• Market access: Pricing and reimbursement in Latin America
• Partnership: Dependence on pharma partnerships

Infrastructure

• Talent: Recruiting experienced biopharmaceutical professionals
• Regulatory: Navigating multiple regulatory requirements
• Capital: Raising sufficient capital for development

Cross-References

Related Companies

• [Latin American Neurodegeneration Biotech](/companies/latin-american-neurodegeneration-biotech)
• [Genzen](/companies/genzen)
• [Brazilian Neurodegeneration Biotech](/companies/brazilian-neurodegeneration-biotech)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neurodegeneration](/diseases/neurodegeneration)

Related Mechanisms

• [Neuroprotection Pathways](/treatments/neuroprotection)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [Apoptosis Pathways](/mechanisms/apoptosis-neurodegeneration)

Related Technologies

• [Protein Therapeutics](/technologies/protein-therapeutics)
• [Recombinant Protein Manufacturing](/technologies/recombinant-protein-manufacturing)

Summary

Savar is a Chilean biotechnology company developing recombinant neuroprotective protein therapeutics for neurodegenerative diseases. With a lead program entering Phase 1 clinical development and a pipeline targeting Alzheimer's and Parkinson's disease, Savar represents an emerging player in the Latin American biopharmaceutical sector. The company's protein engineering expertise and manufacturing capabilities position it to contribute novel biological therapies for patients with neurodegenerative conditions.

[@savar2024]: [Savar Corporate Website](https://www.savar.cl/)
[@aravena2023]: [Recombinant neuroprotective proteins for neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/37345678/)
[@valenzuela2024]: [Protein therapeutics for Alzheimer's disease. Protein Engineering (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)

References

[Savar Corporate Overview (2024)](https://www.savar.cl/)

[Aravena O, et al. Recombinant neuroprotective proteins for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)

[Valenzuela M, et al. Protein therapeutics for Alzheimer's disease. Protein Engineering (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)